Fibrocystic Breast Diagnostics and Treatment Market Overview

Fibrocystic breasts are a non-cancerous disease characterized by round lumps which move freely within the breast tissue and normally swell and shrink with the onset and end of the menstrual cycle. It is projected that 40% of all women in North America are suffering from fibrocystic breast disease. Fibrocystic breast changes are common in women of ages 20- 50. Drinking alcohol may increase the risk of having fibrocystic breast, especially in young women between 18 to 22 years of age. The symptoms are lumps, cyclic breast pain, tenderness, and nipple discharge.Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively

Growing rates of breast cancer and rising awareness on breast cancer monitoring programs are likely to drive the market growth. Moreover, the emergence of advanced and minimally invasive breast biopsy equipment is likely to bring up lucrative opportunities in the untapped market. Nevertheless, factors such as infection risks connected with breast biopsy procedures, ambiguous reimbursement policies, and stringent government regulations play a major role in restricting the market growth. Some more constraints for the Fibrocystic Breast Diagnostics and Treatment Market Growth include the risk associated with the complex surgical procedures and its high cost. These factors are likely to influence the global fibrocystic breasts diagnostics and treatment market negatively.

The worldwide fibrocystic breasts diagnostics and treatment market is estimated to record a substantial growth over the forecast period.The fibrocystic breast disease is a non-cancerous ailment. Fibrocystic breasts feel lumpy and is often painful. The lumps are caused due to fibrocystic changes. The lumps form pertaining to the assemblage of fibrous tissues at a portion of the breast. The scar and ligament tissues are built up of fibrous tissue. The transformation in breast tissue is caused by the changing hormone levels experienced by the ovaries resulting in the development of fibrocystic breasts. The changes appear to be troublesome and leads to painful breast lumps and breast swelling. It mainly occurs in women who are close to their perimenopause and menopause, mostly aged between their 30s and 50s. Prevalence of fibrocystic breast disease increases the risk of breast cancer.

Fibrocystic Breast Diagnostics and Treatment Market Segmentation

• The fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
• On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
• On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
• On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
• The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
• The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Fibrocystic Breast Diagnostics and Treatment Market Regional Analysis

The Americas is likely to lead the fibrocystic breasts diagnostics and treatment market over the forecast period. Increasing rate of surgeries owing to rising healthcare awareness, medical tourism, surge in disposable income, and advancement in technology, are the other factors that influence the fibrocystic breasts diagnostics and treatment market.

Europe market is likely to hold the second largest share globally as fibrocystic breasts diagnostics and treatment market is most common in Germany. The market is expected to grow owing to the growth in the aging population, increasing obesity in the region, and increasing incidents of diabetes.

Many women, almost more than 90% have disturbed progesterone and estrogen levels in some form. The National Institute of Mental Health (NIMH) reports that disturbances in estrogen levels in women, trigger abnormal functioning of the vital brain memory circuit. Brain scans discovered transformed circuit activity which is linked directly to alterations in the sex hormone in women while women are performing a memory task.

In 2018, Asia-Pacific had been anticipated to be the fastest growing market for fibrocystic breast diagnostics and treatment globally. The market is likely to experience growth attributing to the changing lifestyle and increasing elderly population. Additionally, emergence of advanced treatment facilities, better adoption rate, growing demand for innovative technology, surging rate of government initiatives and increasing healthcare investments, pave the way for improvement in the fibrocystic breasts diagnostics and treatment market.

Fibrocystic Breast Diagnostics and Treatment Market Players

• Boston Scientific,
• Argon Medical Devices,
• R. Bard, Inc,
• CareFusion Corporation (Acquired by Becton, Dickinson and Company),
• Devicor Medical Products Inc.,
• Cook Medical, INRAD, Inc.,
• Allergan plc,
• Teva Pharmaceutical Industries Ltd,
• Hologic, Inc.,
• Bayer AG,
• Merck Co., Inc.,
• Pfizer Inc
• Gallini Medical Devices.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/fibrocystic-breasts-diagnostics-treatment-market-6448

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com